Below are showcased publications produced by NOAHE Members. If you are a NOAHE member and would like to have your publication featured on our website and on social media affiliated with the Network, please contact us at noahe@ihe.ca; Not a NOAHE member? Sign up here!

Please note: The publications listed on this page serve to showcase the work of our individual members only, and do not necessarily represent the views of the Network of Alberta Health Economists (NOAHE), NOAHE Members, and/or NOAHE funders.

Filter your search by clicking filters to the left.

Results for: Andrew Sutton Tara Cowling Aidan Hollis

Factors Associated with Drug Shortages in Canada: A Retrospective Cohort Study.

Global clinical trial mobilization for COVID-19: higher, faster, stronger

Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus

Impact of isolation precautions on quality of life: a meta-analysis

One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit

The Impact of Hematopoietic Stem Cell Transplantation on Work and Productivity Loss in Patients with Acute Leukemia: Results from a Rapid Review

An Overview of Liquid Biopsy for Screening and Early Detection of Cancer

How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?

Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta

Multiple Myeloma Treatment Landscape from 2011-2017: Results from the Population-Based "Identifying Outcomes in Real-World Multiple Myeloma"

Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) st

The impact of pharmaceutical rebates on patients’ drug expenditures

Estimating the clinical cost of drug development for orphan versus non-orphan drugs

Bill C-30: who wins and who loses in Canada’s pharmaceutical patent battles?